Equities Analysts Issue Forecasts for Hologic Q4 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Analysts at William Blair lowered their Q4 2025 earnings estimates for Hologic in a report released on Thursday, July 31st. William Blair analyst A. Brackmann now expects that the medical equipment provider will earn $1.08 per share for the quarter, down from their prior forecast of $1.10. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. William Blair also issued estimates for Hologic’s Q1 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.11 EPS, Q4 2026 earnings at $1.15 EPS and FY2026 earnings at $4.47 EPS.

Several other research analysts have also recently commented on HOLX. Raymond James Financial reaffirmed an “outperform” rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. UBS Group lifted their price objective on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, May 27th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $76.42.

Hologic Trading Up 0.5%

Shares of HOLX stock opened at $67.16 on Monday. Hologic has a 12 month low of $51.90 and a 12 month high of $84.67. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average is $64.42 and its two-hundred day moving average is $62.72. The company has a market cap of $14.94 billion, a PE ratio of 27.87, a price-to-earnings-growth ratio of 2.43 and a beta of 0.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The firm’s revenue was up 1.2% on a year-over-year basis.

Hedge Funds Weigh In On Hologic

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Chung Wu Investment Group LLC purchased a new stake in Hologic during the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in shares of Hologic in the 1st quarter worth approximately $34,000. Cromwell Holdings LLC raised its position in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Hologic in the 1st quarter worth approximately $42,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Martin D. Madaus acquired 5,445 shares of the firm’s stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.